BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 17331848)

  • 21. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
    Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients.
    San-Juan R; Comoli P; Caillard S; Moulin B; Hirsch HH; Meylan P;
    Clin Microbiol Infect; 2014 Sep; 20 Suppl 7():109-18. PubMed ID: 24475976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identifying predictive factors for posttransplant lymphoproliferative disease in pediatric solid organ transplant recipients with Epstein-Barr virus viremia.
    Weintraub L; Weiner C; Miloh T; Tomaino J; Joashi U; Benchimol C; Strauchen J; Roth M; Wistinghausen B
    J Pediatr Hematol Oncol; 2014 Nov; 36(8):e481-6. PubMed ID: 24878618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
    Oertel S; Trappe RU; Zeidler K; Babel N; Reinke P; Hummel M; Jonas S; Papp-Vary M; Subklewe M; Dörken B; Riess H; Gärtner B
    Ann Hematol; 2006 Jul; 85(7):478-84. PubMed ID: 16586109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Normalized quantification by real-time PCR of Epstein-Barr virus load in patients at risk for posttransplant lymphoproliferative disorders.
    Jabs WJ; Hennig H; Kittel M; Pethig K; Smets F; Bucsky P; Kirchner H; Wagner HJ
    J Clin Microbiol; 2001 Feb; 39(2):564-9. PubMed ID: 11158107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The IPTA Nashville Consensus Conference on Post-Transplant lymphoproliferative disorders after solid organ transplantation in children: III - Consensus guidelines for Epstein-Barr virus load and other biomarker monitoring.
    Preiksaitis J; Allen U; Bollard CM; Dharnidharka VR; Dulek DE; Green M; Martinez OM; Metes DM; Michaels MG; Smets F; Chinnock RE; Comoli P; Danziger-Isakov L; Dipchand AI; Esquivel CO; Ferry JA; Gross TG; Hayashi RJ; Höcker B; L'Huillier AG; Marks SD; Mazariegos GV; Squires J; Swerdlow SH; Trappe RU; Visner G; Webber SA; Wilkinson JD; Maecker-Kolhoff B
    Pediatr Transplant; 2024 Feb; 28(1):e14471. PubMed ID: 37294621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of virus-specific CD4+ T cells in the control of Epstein-Barr virus infection.
    Mautner J; Bornkamm GW
    Eur J Cell Biol; 2012 Jan; 91(1):31-5. PubMed ID: 21458882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients.
    Wareham NE; Mocroft A; Sengeløv H; Da Cunha-Bang C; Gustafsson F; Heilmann C; Iversen M; Kirkby NS; Rasmussen A; Sørensen SS; Lundgren JD;
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1569-1580. PubMed ID: 29804164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transplantation for congenital heart disease is associated with an increased risk of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in children.
    Offor UT; Bacon CM; Roberts J; Powell J; Brodlie M; Wood K; Windebank KP; Flett J; Hewitt T; Rand V; Hasan A; Parry G; Gennery AR; Reinhardt Z; Bomken S
    J Heart Lung Transplant; 2021 Jan; 40(1):24-32. PubMed ID: 33339556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease.
    Smets F; Latinne D; Bazin H; Reding R; Otte JB; Buts JP; Sokal EM
    Transplantation; 2002 May; 73(10):1603-10. PubMed ID: 12042647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring of Epstein-Barr virus load and killer T cells in pediatric renal transplant recipients.
    Sato T; Fujieda M; Maeda A; Tanaka E; Miyamura M; Chikamoto H; Hisano M; Akioka Y; Ishiura Y; Dohno S; Hattori M; Wakiguchi H
    Clin Nephrol; 2008 Nov; 70(5):393-403. PubMed ID: 19000539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
    Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
    Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
    Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
    Kılınçkaya Doğan H; Mutlu E; Köksoy S; Yılmaz VT; Koçak H; Çolak D; Mutlu D; Günseren F; Dinçkan A; Aliosmanoğlu İ; Süleymanlar G; Gültekin M
    Mikrobiyol Bul; 2016 Apr; 50(2):224-35. PubMed ID: 27175495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction.
    Wagner HJ; Wessel M; Jabs W; Smets F; Fischer L; Offner G; Bucsky P
    Transplantation; 2001 Sep; 72(6):1012-9. PubMed ID: 11579293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder.
    Martinez OM; Krams SM
    Transplantation; 2017 Sep; 101(9):2009-2016. PubMed ID: 28376031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Evaluation of PCR results in the diagnosis of Epstein-Barr virus infections].
    Karadağ Geçgel S; Ersoy A; Sevinir BB; Sınırtaş M; Göral G
    Mikrobiyol Bul; 2012 Oct; 46(4):594-606. PubMed ID: 23188573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Control of Epstein-Barr virus load and lymphoproliferative disease by maintenance of CD8+ T lymphocytes in the T lymphocyte-depleted graft after bone marrow transplantation.
    Torre-Cisneros J; Román J; Torres A; Herrera C; Caston JJ; Rivero A; Mingot E; Rojas R; Martín C; Martínez F; Gómez P
    J Infect Dis; 2004 Nov; 190(9):1596-9. PubMed ID: 15478063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The value of prospective monitoring of Epstein-Barr virus DNA in blood samples of pediatric liver transplant recipients.
    Scheenstra R; Verschuuren EA; de Haan A; Slooff MJ; The TH; Bijleveld CM; Verkade HJ
    Transpl Infect Dis; 2004 Mar; 6(1):15-22. PubMed ID: 15225222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.